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inﬂuenza-like-illness (ILI), work productivity and 
indirect costs (potential cost savings) for the em-
ployer. METHODS: A prospective observational study
was conducted among the workforce of a bank of Bogota
from October 2000 to May 2001, with 2 cohorts:
inﬂuenza vaccinated (volunteers) and not vaccinated. Self-
administered monthly questionnaires collected socio-
economic and health status information, data on ILI
symptoms and sick leaves. Vaccine’s adverse events were
reported one week after injection. Cost-beneﬁt analyses
were performed from the employer perspective using indi-
vidual operating income and salary values. Costs of vac-
cination included vaccine administration and adverse
events. Loss of productivity was assessed by sick leave
days, days of reduced effectiveness at work due to being
not well because of ILI. RESULTS: Among the 759 sub-
jects, 56% vaccinated and 44% not vaccinated, the attack
rates of ILI were respectively 15% versus 47%, with pres-
ence of usual symptoms (cough, chills, muscle aches . . .)
and fever in 93% of the reported ILI. Absence rates for
ILI were similar in the 2 cohorts: 2.6%, with a mean of
3.1 days of sick leave, as well as the proportions of people
feeling not well because of ILI: 93%, with a mean of 4
days before being well again. Using the realistic hypoth-
esis of a reduced effectiveness of 30% when the patient
is not well because of ILI, global cost savings were
US$7469 for the study population and US$59 per indi-
vidual i.e. a cost-beneﬁt ratio of 20%. CONCLUSIONS:
Among the studied volunteers, ILI has signiﬁcant impact
on work productivity, in terms of indirect costs, even if
considering lower work effectiveness rates’ hypotheses, in
conditions of mild outbreak of inﬂuenza. Possible expan-
sion of inﬂuenza vaccination to all the company could
lead to important employer cost savings.
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VACCINATION IN HEALTHY WORKING
ADULTS:WHAT RETURN ON INVESTMENT FOR
COMPANIES? AN INTERNATIONAL
PERSPECTIVE
Anne T, Plun-Favreau J
Aventis Pasteur International, Lyon, France
OBJECTIVE: In healthy working adults, it has been doc-
umented that vaccination programs may yield cost-
savings by avoiding absenteeism and loss of productivity.
However few studies provide an international perspec-
tive. The objective of this project is to develop a multi-
national measurement of the cost-beneﬁt aspect of
vaccination programs against inﬂuenza, typhoid fever and
hepatitis A in an adult population working in various
countries and industrial sectors. METHODS: A cost-
beneﬁt model has been developed in order to calculate the
cost-beneﬁt result of vaccination programs. The costs of
the vaccination alternative, including associated immu-
nization services are thus compared to the beneﬁts i.e.
avoided absenteeism and loss of productivity by prevent-
ing the diseases. Those beneﬁts are represented by three
different items being 1) Avoided loss of labor costs; 2)
Avoided cost of replacement; and 3) Avoided loss of oper-
ating income. Companies published ﬁnancial data from
four countries (Australia, Turkey, Brazil and Philippines)
have been sampled and gathered in order to yield an
average cost-beneﬁt result by country. A sensitivity analy-
sis and break-even analysis have been performed on the
main criteria involved in the calculation. RESULTS:
Considering the three diseases, the results obtained 
show an average cost of diseases for 100 employees 
of US$11,086.81 per year. The net cost-savings per
employee vaccinated and per year ranged from US$13.54
(in the Philippines) to US$80.17 (in Turkey). CONCLU-
SION: This predictive approach aimed at assessing the
return on investment for companies in case of funding a
vaccination program proposed to the employees. The 
simulations based on aggregated published ﬁnancial data
show a cost-savings speciﬁc to each country for different
industrial sectors. It deserves further analysis on a larger
sample of companies in other countries and industrial
sectors.
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OBJECTIVES: In developing and transitional countries,
poor injection practices transmit potentially life-
threatening pathogens. We modelled the cost effectiveness
of safe and appropriate use of injections policies in terms
of cost per Disability Adjusted Life Year (DALY) pre-
vented. METHODS: A mass action model estimated the
incidence of injection-associated Hepatitis B Virus (HBV),
Hepatitis C Virus (HCV) and Human Immunodeﬁciency
Virus (HIV) infections. We reviewed the effectiveness of
interventions to reduce injection overuse or unsafe prac-
tices. DALYs were age-adjusted and 3% discounted. We
quantiﬁed the resources needed to implement effective
interventions and estimated their cost by region. The cost
effectiveness compared the effects of a “Do nothing” sce-
nario with that of an intervention on a theoretical 2000
cohort using WHO Global Burden of Disease regions and
a 30-year analytic horizon. RESULTS: Preliminary results
suggest that worldwide, re-use of injection equipment in
2000 accounted for 32%, 40% and 5% of new HBV,
HCV and HIV infections respectively, causing the loss 
of 9,177,679 DALYs between 2000 and 2030. Interven-
tions in 2000 for the safe (provision of single-use sy-
ringes, average effectiveness: 95%) and appropriate 
use (patients-providers interactional group discussions,
average effectiveness: 30%) would prevent 8,856,460
DALYs and cost US$463.4 million (range by region of the
cost per DALY prevented: 6.7–1652). Compared to other
regions, the cost per DALY prevented was lower in
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regions where re-use exceeded 15% (US$55.5 versus
US$791.5) and in regions where HIV prevalence exceeded
1% (US$13.29 versus US$434.1). Uncertainty analysis
identiﬁed the HIV-attributable fraction and the number
of syringes and needles required as key sources of uncer-
tainty. CONCLUSION: Safe and appropriate use of injec-
tion policies are cost-effective, particularly in countries
where re-use of injection equipment is common or where
the HIV epidemic is generalized.
INFECTION—Quality of Life/Utility
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OBJECTIVES: We measured adherence to and satisfac-
tion with anti-HIV treatment and quality of life (QoL) of
a sample of Italian patients (pts). METHODS: We carried
out a perspective, multicentre observational survey. Pts
who needed a simpler antiretroviral treatment were 
asked to ﬁll in both a questionnaire for measuring 
adherence/satisfaction with therapy (PMAQ-7) and a
QoL one (MOS-HIV). Questionnaires were administered
at baseline (change of therapy) and 3 months later.
RESULTS: From March to December 2001, 45 centres
enrolled 407 pts (285 fully evaluable). Males were
69.5%, mean age was 38 years. HIV infection was mainly
due to IV drug use (44%) and heterosexual intercourse
(36%). Baseline treatments were: 2NRTI + 1 or more PI
(68%), 2NRTI + 1NNRTI (12%), 3NRTI (10%), other
(10%). Treatments changed as follow: 2NRTI + 1 or
more PI (20%), 2NRTI + 1NNRTI (33%), 3NRTI (43%;
in this group 102 out of 122pts, 84%, on Trizivir), other
(5%). Reasons for changing therapy (multiple reasons
allowed) were high pill burden (45%), side effects (29%),
high number of assumptions (26%), failure due to poor
compliance (18%), dietary requirements (17%), ﬁxed
time of assumption (12%), other (13%). After switching,
scores of both questionnaires increased in all pts, meaning
better compliance and QoL. Effect sizes (ES) of PMAQ-
7 score showed that the highest values were related to
PMAQ-7 adherence (0.28) and scheduling (0.75); highest
values were reported in scheduling among pts treated
with 3NRTI (ES 1.01). Highest ES of MOS-HIV were in
health transition (0.5) and MOS-HIV QoL (0.38); highest
values were reported in health transition among pts
treated with 3NRTI (ES 0.69). CONCLUSIONS: We con-
clude that a simpler therapy could improve both HIV
patient adherence and QoL.
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OBJECTIVES: To critically review available instruments
for assessing quality of life (QoL) and health-related QoL
(HRQL) in HIV and AIDS, with speciﬁc reference to suit-
ability for clinical trials. METHODS: Literature searches
were conducted using Medline, AIDSLine and PsycINFO
to identify instruments used to measure QoL or HRQL
in HIV and/or AIDS since 1990. Relevant literature per-
taining to such measures was critically reviewed. Instru-
ments were appraised according to the following issues:
development (theoretical basis, content derivation); psy-
chometric properties (dimensionality, test-retest reliabil-
ity, internal consistency, face/content validity, construct
validity, responsiveness); practicality for clinical trials
(length, complexity, method/ease of administration and
scoring); cultural considerations (language availability,
cross-cultural validity, translation/adaptation methodol-
ogy); and application in HIV/AIDS populations (study
type, sample characteristics). RESULTS: Sixteen instru-
ments were selected for review; 5 HIV/AIDS-speciﬁc
(HAT-QoL, MQoL-HIV, LWHIV, HIV-QL31, FQLS), 
3 adaptations of cancer-speciﬁc instruments (HOPES,
FAHI, QLQ-C30 + HIV Module), 3 adaptations of
generic instruments (MOS-HIV, HIV-PARSE, AIDS-
HAQ), and the 5 most commonly employed generic
instruments in HIV/AIDS (SF-36, SF-20, QWB, EQ-5D,
QL-Index). Overall, the conceptual quality of the instru-
ments reviewed was poor, with most lacking a theore-
tical model of the intended construct. As such, none of
the instruments measure QoL, with most assessing the
various dimensions of HRQL. The content of most of the
instruments was derived without reference to patients
with HIV/AIDS and, thus, would have limited applica-
bility to this patient group. The HAT-QoL, MQoL-HIV
and FAHI comprised items that appeared better targeted
to the issues of relevance to patients with HIV or AIDS.
However, the psychometric properties of the HAT-QoL
and MQoL-HIV were poor. CONCLUSIONS: Of the
instruments reviewed, the FAHI appears to be the most
appropriate instrument for measuring HRQL in clinical
trials. However, a number of its properties have yet to be
adequately assessed (including face/content validity, test-
retest reliability and unidimensionality of its scales).
